About

Provided by Ropes & Gray LLP

Today’s life sciences industry faces myriad challenges, including complex regulation, steep competition and ever-changing technologies. Companies around the world turn to Ropes & Gray’s global life sciences group for internationally recognized counsel on virtually all matters impacting their businesses.

We work across practices and geographies to develop cutting-edge solutions that help our clients meet their business goals.

In addition to advising biotechnology, pharmaceutical and medical device companies, we also work with:

Investment banks, venture capital and private equity firms, royalty monetization firms, private investment and hedge funds, and individual investors focused on funding life sciences-related companies

Food, dietary supplement, cosmetics and consumer product companies

Academic medical centers and research institutions

Veterinary, agricultural and industrial applications

Drawing on resources in our offices around the globe, we focus on developing cutting-edge solutions to help clients meet their business goals. Our practice includes:

Mergers & acquisitions

Licensing, collaborations & joint ventures

Public and private financings and SEC compliance

FDA regulatory and health care compliance

China regulatory & compliance

Government enforcement / white collar crime

Intellectual property

Securities & futures enforcement

Antitrust

Tax

To learn more about our practice, please visit: https://www.ropesgray.com/practices/life-sciences.aspx

Chambers Review

Provided by Chambers
Life Sciences - Asia-Pacific Region
2
Band 2
What the team is known for

Ropes & Gray has impressively broad coverage of cross-border investments, licensing, corporate and compliance matters, especially those relating to the FCPA. The firm is prominent for its core expertise in transactional and regulatory matters, particularly the Shanghai and Hong Kong offices, while the Seoul team is notable for its IP expertise. It has experience in handling cross-border licensing and commercialisation agreements and leverages its capital markets expertise to act on IPOs and other related matters for clients in this industry. The firm retains a standout client roster of multinational biotech, pharmaceutical and healthcare companies and draws upon the support of US colleagues to advise on inbound and outbound transactions.

Notable practitioners

Arthur Mok and Katherine Wang in Shanghai are key contacts for clients.

Work Highlights

Provided by Ropes & Gray LLP
  • Ropes & Gray advised Pediatrix Therapeutics on its licensing agreement with Aclaris Therapeutics to develop and commercialise ATI-1777 in China.

Strengths

Provided by Chambers